

# Andrew Bate

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8689633/andrew-bate-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77  
papers

3,076  
citations

28  
h-index

54  
g-index

85  
ext. papers

3,670  
ext. citations

5  
avg, IF

5.17  
L-index

#	Paper	IF	Citations
77	Black Swan Events and Intelligent Automation for Routine Safety Surveillance.. <i>Drug Safety</i> , <b>2022</b> , 45, 419-427	5.1	0
76	Artificial Intelligence Based on Machine Learning in Pharmacovigilance: A Scoping Review.. <i>Drug Safety</i> , <b>2022</b> , 45, 477-491	5.1	0
75	Safety of medicines and vaccines - building next generation capability. <i>Trends in Pharmacological Sciences</i> , <b>2021</b> , 42, 1051-1063	13.2	3
74	Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 111, 310	6.1	2
73	Artificial Intelligence, Real-World Automation and the Safety of Medicines. <i>Drug Safety</i> , <b>2021</b> , 44, 125-133	5.1	14
72	Developing Crowdsourced Training Data Sets for Pharmacovigilance Intelligent Automation. <i>Drug Safety</i> , <b>2021</b> , 44, 373-382	5.1	2
71	Choosing Among Common Data Models for Real-World Data Analyses Fit for Making Decisions About the Effectiveness of Medical Products. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 827-833	6.1	14
70	Transparent Reporting on Research Using Unstructured Electronic Health Record Data to Generate Real WorldSEvidence of Comparative Effectiveness and Safety. <i>Drug Safety</i> , <b>2019</b> , 42, 1297-1309	5.1	6
69	A Novel Approach to Visualize Risk Minimization Effectiveness: Peeping at the 2012 UK Proton Pump Inhibitor Label Change Using a Rapid Cycle Analysis Tool. <i>Drug Safety</i> , <b>2019</b> , 42, 1365-1376	5.1	
68	Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden. <i>JAMA Oncology</i> , <b>2019</b> , 5, 1633-1635	13.4	52
67	Data Mining and Other Informatics Approaches to Pharmacoepidemiology <b>2019</b> , 675-700		
66	The International Society for Pharmacoepidemiology's Comments on the Core Recommendations in the Summary of the Heads of Medicines Agencies (HMA) - EMA Joint Big Data Task Force. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 1640-1641	2.6	1
65	The Role of Pharmacoepidemiology in Industry <b>2019</b> , 98-125		1
64	An Implementation and Visualization of the Tree-Based Scan Statistic for Safety Event Monitoring in Longitudinal Electronic Health Data. <i>Drug Safety</i> , <b>2019</b> , 42, 727-741	5.1	4
63	Lessons from meta-analyses of randomized clinical trials for analysis of distributed networks of observational databases. <i>Pharmaceutical Statistics</i> , <b>2019</b> , 18, 65-77	1	4
62	Time Series Disturbance Detection for Hypothesis-Free Signal Detection in Longitudinal Observational Databases. <i>Drug Safety</i> , <b>2018</b> , 41, 565-577	5.1	7
61	Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System's analytic tools. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 332-339	2.6	12

60	Signal Detection for Recently Approved Products: Adapting and Evaluating Self-Controlled Case Series Method Using a US Claims and UK Electronic Medical Records Database. <i>Drug Safety</i> , <b>2018</b> , 41, 523-536	5.1	9
59	From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging Sources. <i>Drug Safety</i> , <b>2018</b> , 41, 143-149	5.1	37
58	A Case Study of the Incremental Utility for Disease Identification of Natural Language Processing in Electronic Medical Records. <i>Pharmaceutical Medicine</i> , <b>2018</b> , 32, 31-37	2.3	4
57	Assessing performance of sequential analysis methods for active drug safety surveillance using observational data. <i>Journal of Biopharmaceutical Statistics</i> , <b>2018</b> , 28, 668-681	1.3	0
56	Real World Evidence: Time for a Switch?. <i>Drug Safety</i> , <b>2018</b> , 41, 1309-1312	5.1	2
55	Developing a Crowdsourcing Approach and Tool for Pharmacovigilance Education Material Delivery. <i>Drug Safety</i> , <b>2017</b> , 40, 191-199	5.1	6
54	Guidance to reinforce the credibility of health care database studies and ensure their appropriate impact. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 1013-1017	2.6	7
53	Good Signal Detection Practices: Evidence from IMI PROTECT. <i>Drug Safety</i> , <b>2016</b> , 39, 469-90	5.1	65
52	Computer-assisted expert case definition in electronic health records. <i>International Journal of Medical Informatics</i> , <b>2016</b> , 86, 62-70	5.3	25
51	Designing and incorporating a real world data approach to international drug development and use: what the UK offers. <i>Drug Discovery Today</i> , <b>2016</b> , 21, 400-5	8.8	21
50	Evidence generation from healthcare databases: recommendations for managing change. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25, 749-54	2.6	10
49	Hip/femur fractures associated with the use of benzodiazepines (anxiolytics, hypnotics and related drugs): a methodological approach to assess consistencies across databases from the PROTECT-EU project. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25 Suppl 1, 66-78	2.6	30
48	Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25 Suppl 1, 79-87	2.6	11
47	Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25 Suppl 1, 56-65	2.6	73
46	Prevalence of antibiotic use: a comparison across various European health care data sources. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25 Suppl 1, 11-20	2.6	40
45	Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case-control studies using two primary care databases in Europe. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25 Suppl 1, 29-38	2.6	14
44	A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance. <i>Drug Safety</i> , <b>2015</b> , 38, 749-65	5.1	38
43	Teaching pharmacovigilance: the WHO-ISoP core elements of a comprehensive modular curriculum. <i>Drug Safety</i> , <b>2014</b> , 37, 743-59	5.1	31

42	Quantitative Signal Detection and Analysis in Pharmacovigilance <b>2014</b> , 331-354		10
41	An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance. <i>Drug Safety</i> , <b>2013</b> , 36, 119-34	5.1	52
40	Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. <i>Statistical Methods in Medical Research</i> , <b>2013</b> , 22, 57-69	2.3	107
39	Disproportionality methods for pharmacovigilance in longitudinal observational databases. <i>Statistical Methods in Medical Research</i> , <b>2013</b> , 22, 39-56	2.3	68
38	Drug Adverse Event Detection in Health Plan Data Using the Gamma Poisson Shrinker and Comparison to the Tree-based Scan Statistic. <i>Pharmaceutics</i> , <b>2013</b> , 5, 179-200	6.4	15
37	Defining Surveillance in drug safety. <i>Drug Safety</i> , <b>2012</b> , 35, 347-57	5.1	15
36	Terminological challenges in safety surveillance. <i>Drug Safety</i> , <b>2012</b> , 35, 79-84	5.1	11
35	Safety surveillance of longitudinal databases: results on real-world data. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 673-675	2.6	7
34	Dose variations associated with formulations of NSAID prescriptions for children: a descriptive analysis of electronic health records in the UK. <i>Drug Safety</i> , <b>2011</b> , 34, 307-17	5.1	4
33	Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase. <i>Drug Safety</i> , <b>2011</b> , 34, 253-66	5.1	18
32	Safety surveillance of longitudinal databases: methodological considerations. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2011</b> , 20, 714-7	2.6	16
31	Pneumonia following antipsychotic prescriptions in electronic health records: a patient safety concern?. <i>British Journal of General Practice</i> , <b>2010</b> , 60, e385-94	1.6	25
30	Temporal pattern discovery in longitudinal electronic patient records. <i>Data Mining and Knowledge Discovery</i> , <b>2010</b> , 20, 361-387	5.6	118
29	Large-scale regression-based pattern discovery: The example of screening the WHO global drug safety database. <i>Statistical Analysis and Data Mining</i> , <b>2010</b> , 3, 197-208	1.4	47
28	Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. <i>British Journal of Clinical Pharmacology</i> , <b>2009</b> , 68, 427-34	3.8	40
27	Sudden cardiac death in users of second-generation antipsychotics. <i>Journal of Clinical Psychiatry</i> , <b>2009</b> , 70, 1725-6	4.6	2
26	Drug-drug interactions - a preventable patient safety issue?. <i>British Journal of Clinical Pharmacology</i> , <b>2008</b> , 65, 144-6	3.8	38
25	Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions. <i>Drug Safety</i> , <b>2008</b> , 31, 685-94	5.1	53

24	Impact of stratification on adverse drug reaction surveillance. <i>Drug Safety</i> , <b>2008</b> , 31, 1035-48	5.1	42
23	Stratification for spontaneous report databases. <i>Drug Safety</i> , <b>2008</b> , 31, 1145-7	5.1	9
22	Abacavir and increased risk of myocardial infarction. <i>Lancet, The</i> , <b>2008</b> , 372, 805	4.0	1
21	Temporal pattern discovery for trends and transient effects <b>2008</b> ,		27
20	A statistical methodology for drug-drug interaction surveillance. <i>Statistics in Medicine</i> , <b>2008</b> , 27, 3057-70.	2.3	91
19	Duplicate detection in adverse drug reaction surveillance. <i>Data Mining and Knowledge Discovery</i> , <b>2007</b> , 14, 305-328	5.6	79
18	Data mining in drug safety: Side effects of drugs essay. <i>Side Effects of Drugs Annual</i> , <b>2007</b> , 29, xxxiii-xlvi	0.2	8
17	Bayesian confidence propagation neural network. <i>Drug Safety</i> , <b>2007</b> , 30, 623-5	5.1	32
16	Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. <i>Statistics in Medicine</i> , <b>2006</b> , 25, 3740-57	2.3	108
15	Data mining in spontaneous reports. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2006</b> , 98, 324-30	3.1	25
14	Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. <i>Lancet, The</i> , <b>2005</b> , 365, 482-7	4.0	307
13	A hit-miss model for duplicate detection in the WHO drug safety database <b>2005</b> ,		17
12	A bayesian recurrent neural network for unsupervised pattern recognition in large incomplete data sets. <i>International Journal of Neural Systems</i> , <b>2005</b> , 15, 207-22	6.2	21
11	Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. <i>International Clinical Psychopharmacology</i> , <b>2003</b> , 18, 157-61	2.2	7
10	Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. <i>International Clinical Psychopharmacology</i> , <b>2003</b> , 18, 157-161	2.2	38
9	A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2002</b> , 11, 3-10	2.6	572
8	A data mining approach for signal detection and analysis. <i>Drug Safety</i> , <b>2002</b> , 25, 393-7	5.1	94
7	Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. <i>BMJ: British Medical Journal</i> , <b>2001</b> , 322, 1207-9		151

6	A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. <i>Drug Safety</i> , <b>2000</b> , 23, 533-42	5.1	144
5	Bayesian Neural Networks used to Find Adverse Drug Combinations and Drug Related Syndromes. <i>Perspectives in Neural Computing</i> , <b>2000</b> , 215-220		2
4	From association to alert—a revised approach to international signal analysis. <i>Pharmacoepidemiology and Drug Safety</i> , <b>1999</b> , 8, S15-S25	2.6	10
3	From association to alert—a revised approach to international signal analysis. <i>Pharmacoepidemiology and Drug Safety</i> , <b>1999</b> , 8 Suppl 1, S15-25	2.6	54
2	Data Mining in Pharmacovigilance 339-377		2
1	Data Mining in Pharmacovigilance: A View from the Uppsala Monitoring Centre 265-275		